Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abaloparatide - Ipsen/Radius Health

Drug Profile

Abaloparatide - Ipsen/Radius Health

Alternative Names: Abaloparatide patch; Abaloparatide-SC; Abaloparatide-sMTS; Abaloparatide-TD; BA-058; BA-058-SC; BA-058-TD; BIM-44058; Eladynos; ITM-058; Ostabalo; Ostabaro; PBK-L2201; PBK_L2201; PTHrP; Synthetic human parathyroid hormone 37-70 analogue - Ipsen; TYMLOS

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Drug Delivery Systems; Biomeasure Inc; Ipsen
  • Developer Radius; Radius Health Inc.; Teijin Pharma
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis
  • Registered Male osteoporosis; Osteoporosis

Most Recent Events

  • 07 Dec 2023 PharmaBio Korea plans the phase III Bridge trial for Osteoporosis (In adults, In the elderly) in South Korea (SC) (NCT06154187)
  • 20 Mar 2023 Registered for Postmenopausal osteoporosis in European Union (SC)
  • 20 Dec 2022 Registered for Male osteoporosis (In the elderly, In adults) in USA (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top